Uncategorized
Ocular Therapeutix submits premarket approval application for hydrogel sealant
Ocular Therapeutix has submitted a premarket approval application to the U.S. Food and Drug Administration for ReSure sealant, according to a company news release.The sealant, which uses the company’s proprietary hydrogel technology, has the proposed indication of intraoperatively managing clear corneal incisions with a wound leak and preventing fluid egress after cataract surgery or IOL placement, the release said.